The 5-methylcytosine (5-mC) derivative 5-hydroxymethylcytosine (5-hmC) is abundant in the brain for unknown reasons. Here we characterize the genomic distribution of 5-hmC and 5-mC in human and mouse tissues. We assayed 5-hmC by using glucosylation coupled with restriction-enzyme digestion and microarray analysis. We detected 5-hmC enrichment in genes with synapse-related functions in both human and mouse brain. We also identified substantial tissue-specific differential distributions of these DNA modifications at the exon-intron boundary in human and mouse. This boundary change was mainly due to 5-hmC in the brain but due to 5-mC in non-neural contexts. This pattern was replicated in multiple independent data sets and with single-molecule sequencing. Moreover, in human frontal cortex, constitutive exons contained higher levels of 5-hmC relative to alternatively spliced exons. Our study suggests a new role for 5-hmC in RNA splicing and synaptic function in the brain.
The recent rediscovery of 5-hmC in mammals [1] [2] [3] demonstrates that covalent DNA modifications are more dynamic than previously believed. The oxidation of 5-mC generates 5-hmC in a reaction mediated by the ten-eleven translocation (TET) family of enzymes (TET1, TET2 or TET3) 3 . Traditional means of assaying DNA modifications either have been unable to differentiate between 5-mC and 5-hmC (for example, bisulfite mapping 4 ) or have been specific for 5-mC (for example, antibodies against 5-mC). 5-hmC is particularly enriched in the brain relative to other tissues, as observed in mice and humans 1, 5 . At gene promoters, 5-mC suppresses transcription by recruiting transcriptional repressors 6 . In the mouse cortex and cerebellum, 5-hmC is enriched within genes and appears to increase with increasing transcription levels 7, 8 . In addition to being an intermediate state of complete DNA demethylation, 5-hmC also effects functional demethylation by suppressing binding of transcriptional repressors [9] [10] [11] [12] . Synchronous neuronal activity promotes active DNA demethylation of plasticityrelated genes in the mouse brain through TET-mediated formation of 5-hmC (ref. 9) ; however, it is not known whether such demethylation completely accounts for the enrichment of 5-hmC in the brain.
We mapped both 5-mC and 5-hmC in a variety of neuronal and non-neuronal tissues from mice and humans to investigate their respective roles. We labeled 5-hmC using the phage enzyme β-glucosyltransferase (BGT), followed by differential digestion of DNA with restriction enzymes either sensitive or insensitive to these DNA modifications (Fig. 1a) . The resulting DNA fragments were amplified and analyzed by genome-wide tiling microarray (Supplementary Table 1 ). This assay has the advantage of mapping modifications at up to single-CpG resolution, which was crucial for our ability to connect differences in DNA modifications to exonintron boundaries.
RESULTS

Validation of 5-hmC assay
BGT transfers a glucose molecule specifically to the hydroxymethyl group of 5-hmC, thus rendering it resistant to digestion by the methylation-insensitive MspI enzyme at the C hm CGG target site 13, 14 ( Supplementary Fig. 1a) . Thus, 5-hmC abundance is estimated by differential resistance to MspI digestion with and without glucosylation of genomic DNA (gDNA). HpaII targets the same site, CCGG, yet it cannot cut C m CGG or C hm CGG, so comparing HpaII digestion with MspI digestion provides a measure of both 5-mC and 5-hmC abundance. Subtraction of the 5-hmC estimate r e s o u r c e from the HpaII-based estimate therefore measures 5-mC. We used biochemical, molecular biological and in silico methods to validate the assay combining glucosylation and restriction-enzyme digestion to measure 5-hmC (Supplementary Figs. 1 and 2 and Supplementary Tables 2 and 3). We verified that the addition of a glucose moiety to 5-hmC confers resistance to MspI digestion of modified oligonucleotides ( Supplementary Figs. 1 and 2) . We also confirmed that gDNA modifications can be measured on tiling microarrays (Fig. 1b) . Volcano plots demonstrated that nontarget sequences are not affected by DNA glucosylation, as shown by a symmetric zero-centered distribution of intensities, whereas signals from target probes (right) were shifted to the upper right, indicating protection of MspI targets after DNA glucosylation. These analyses also confirmed that mouse brain samples contain relatively higher 5-hmC densities than do other tissues, as evidenced by a greater shift in the corresponding volcano.
For microarray normalization, we chose an algorithm that corrected for affinity bias due to probe sequence, a known issue for tiling arrays 15 . We compared two sequence-based normalization algorithms using modification estimates from quantitative polymerase chain reaction (qPCR) (Supplementary Note 1, Supplementary Fig. 2a and Supplementary Tables 2 and 3) and selected an algorithm described previously 16 (Supplementary Note 2) . We also found that single-probe estimates for 5-hmC or 5-mC provided less bias while maintaining precision for these data, as compared to averaging probe intensities in a local window (Supplementary Table 2 ). Despite the increased variance in single-probe estimates, biological variability across samples significantly exceeded variability in technical replicates (Supplementary Fig. 2b ; for example, probe-wise increase due to biological variability relative to technical variability, mean = 0.52 (arbitrary units), 95% CI, [0.51,0.53]; P < 10 −16 , one-sample t test).
Average probe intensities had the relative magnitude expected from the three treatments: MspI-digested nonglucosylated gDNA had the lowest intensity (for example, in mouse tissues, mean ± s.d., −1.45 ± 1.00 (arbitrary units); 134,521 target probes), followed by MspI-digested glucosylated gDNA (−1.35 ± 1.00). HpaII-digested nonglucosylated gDNA had the highest intensity (−0.81 ± 1.03).
Negative values reflect the digestion (under-representation) of target sites relative to the baseline of undigested sequences.
Characterization of 5-mC and 5-hmC in adult-mouse tissues
Using thin-layer chromatography (TLC) and intensities from microarray probes, we verified that 5-hmC levels were the highest in gDNA of the mouse brain, compared to liver, kidney, pancreas and heart (Supplementary Tables 4 and 5 ). This finding is consistent with previous reports 1, 5 . To investigate the origin of the increased levels of 5-hmC in the brain, we identified genes and intergenic regions with significantly different 5-hmC in the mouse brain compared to other tissues. Of 134,521 probes that overlapped the nonrepetitive genome (six chromosomes), 73,461 overlapped genes (defined by Mouse Genome Informatics (MGI) symbol; 2-238 probes per gene; median, 16.8). Out of 4,357 genes tested, 730 had different 5-hmC levels in the brain relative to the other tissues (repeated-measures analysis of variance (ANOVA) P < 10 −2 , false discovery rate Q < 0.05; Supplementary Table 6 ). All but one gene had higher 5-hmC and lower 5-mC levels in the brain. Even within the brain, these genes contained above-average 5-hmC levels (P < 10 −4 , bootstrapping (no replacement); median 5-hmC of randomly sampled genes (R = 10,000)). Separately, we identified 83 differential intergenic probes that also had significantly higher 5-hmC levels in the brain (probe-wise linear regression, total of 60,721 intergenic probes, Q < 0.05; Supplementary Table 7) .
We further explored possible associations of genic 5-hmC and steady-state mRNA levels in the mouse data set. We related 5-hmC and 5-mC intensity levels from our microarrays to tissue-specific mRNA levels from a previously published data set 17 (Supplementary Note 2). In three out of five tissues investigated, 5-hmC showed a significant increase in genes with higher transcript abundance (Fig. 1c Supplementary Fig. 3 ). This trend was also observed in the brain, but it did not reach statistical significance (P = 0.17, linear regression; Fig. 1c and Supplementary Fig. 3) ; the same was true for the 730 genes identified to have higher 5-hmC levels (P = 0.06, bootstrapping randomly-sampled genes (R = 10,000)). In contrast, genic levels of 5-mC significantly decreased for genes with increased mRNA levels in all five tissues ( Fig. 1c and Supplementary Fig. 3 ).
Synaptic protein genes enriched for 5-hmC in mouse brain
To determine whether the 730 genes identified above had unifying cellular functions, we performed a functional overrepresentation analysis (DAVID 18 , background set of 4,357 genes tested). We observed that these genes were statistically overrepresented in eight Gene Ontology (GO) terms (total 156 candidate terms), which in turn were associated with synapse function ( Table 1 ). The top overrepresented terms were 'cell adhesion' (Q = 1.3 × 10 −6 ), 'plasma membrane' (Q = 8.7 × 10 −5 ) and 'synapse' (Q = 3.5 × 10 −4 ). These genes also had functional annotation clusters pertaining to ion-channel activity, Rho GTPase signaling and neuronal development (Supplementary Table 8 ). Notably, some of these 5-hmC-rich genes showed transcript enrichment or specificity for non-neuronal brain cells. We identified the cell-type specificity of the 730 brain enriched genes by using a list from a previously published transcriptomic data set of individual brain-cell populations 19 (Supplementary Note 2). Using this list, we found that 25 of the brain enriched genes (3%) had enriched transcription in astrocytes, 21 (3%) in oligodendrocytes and 57 (8%) in neurons (Supplementary Table 9 ). By this definition, a few genes were also specific to the cell type (astrocytes, Rfx4, Gli3; oligodendrocytes, Elovl7, Cpm; neurons, Nts, Syt1, Nrg3, Trhde, Kcnc2, Clstn2). We tested to see whether the increase in brain 5-hmC observed in the 730 identified genes could be generalized to the entire functional class of synapse-related genes. We compared average 5-hmC in all genes mapped to the synapse-relevant GO terms to that in genes outside these categories 20 (Supplementary Note 2) . Genes within each tested category ('synapse' and 'synapse part' , 'cell adhesion' , 'plasma membrane') had significantly higher 5-hmC levels (for example, for 'synapse' , n = 3,258 probes) than did genes not mapped to the category (n = 70,203; P = 3.2 × 10 −20 , two-tailed Wilcoxon-MannWhitney (WMW) test; Fig. 2a and Supplementary Fig. 4 ). This effect persisted after controlling for GC content of the probe sequence, a parameter that could artificially influence probe intensity.
Enrichment of 5-hmC in synapse genes extends to human brain
We extended the comparison of 5-hmC enrichment in synapse-related genes to the human brain by assaying gDNA from 28 human postmortem brains (frontal cortex Brodmann area 10 (BA10); Stanley Medical Research Institute and Harvard Brain Tissue Resource Center; details in Supplementary Table 10 ). Human gDNA samples were processed in the same way as for the mouse gDNA samples (Supplementary Note 2) and assayed with Affymetrix 2.0R human whole-genome tiling microarrays E and F (Supplementary Table 1 shows probe counts). Similar to the mouse brain, the human frontal cortex had higher 5-hmC levels within genes that mapped to the GO terms 'synapse' , 'synapse part' , 'cell adhesion' and 'plasma membrane' ('synapse' and 'synapse part' , P = 1.0 × 10 −4 , one-tailed WMW test; Fig. 2b and Supplementary Fig. 5 ).
5-hmC marks the exon-intron boundary in the human brain
Several studies performed before the rediscovery of 5-hmC have noted a change in the density of modified cytosines at the exonintron boundary of genes, with the density being higher on the exonic side 21, 22 . These studies, however, used bisulfite sequencing and therefore did not differentiate between 5-mC and 5-hmC. As our restriction enzyme-based assay provided single-nucleotide resolution mapping of DNA modifications, we compared densities of each modification on either side of the exon-intron boundary (linear mixed-effects model, described in Online Methods). Distances to the boundary were measured from the second C of the target sequence (CCGG). DNA-modification differences at exon-intron boundaries are reported for two regions: one immediately adjacent to the boundary (cumulative distance for the first 5 nucleotides, denoted d = 5 base pairs (bp)) and one that captures the general periboundary trend (cumulative distance for the first 20 nucleotides, denoted d = 20 bp). Relevant parameters (for example, probe count) and statistics for all data sets are in Supplementary Table 11 . Overall probe intensities for various DNA modifications in all data sets are in Supplementary Table 12 .
Levels of all DNA modifications changed at the exon-intron boundary in human frontal cortex samples (n = 28 brain samples; Affymetrix tiling microarrays E and F, covering six chromosomes). We found higher densities of both modifications in exons relative to introns, consistent with previous findings (d = 5 bp, P = 2. Fig. 3a,b) . The change in 5-hmC relative to 5-mC was most evident in the first 5-10 bp from the boundary. For longer distances (up to 50 bp tested), both modifications showed robust increases in exons relative to introns ( Fig. 3b and Supplementary Fig. 6a ).
We also mapped DNA modifications in brain samples from patients diagnosed with schizophrenia and bipolar disorder 23 , collectively termed 'major psychosis' (n = 54 brain samples (frontal cortex BA10); Affymetrix tiling microarray E). Consistent with the findings in the control brain set reported above, gDNA from brains of patients with psychosis also showed a predominant change in 5-hmC at the exonintron boundary at both distances (Fig. 3b, Supplementary Table 11 and Supplementary Fig. 6b ).
To ascertain whether the cross-boundary change was unique to brain tissue in humans, we analyzed human liver samples (n = 13) in parallel with age-and sex-matched frontal cortex samples (Supplementary Table 10 ). Here again, brain gDNA samples showed a larger change in 5-hmC than in 5-mC. In contrast, liver gDNA samples showed a predominant change in 5-mC, both at the boundary (d = 5 bp, P = 4.8 × 10 −6 ) and at longer distances (d = 20 bp, P = 4.8 × 10 −12 ) (Fig. 3c,d,  Supplementary Fig. 6c,d and Supplementary Table 11) .
5-mC and 5-hmC boundary changes validated in human brain
We validated the findings in the human frontal cortex using three independent methods. First, to estimate the impact of GC differences in exons and introns, we compared probes representing introns to those representing exons, after matching for GC content and the distance from the boundary (100 iterations to sample a greater number of exonic probes). The overall trends of 5-hmC and 5-mC for matched probes were similar to those for unmatched probes ( Supplementary  Fig. 6e ). Cross-boundary differences in 5-hmC were significant (P < 0.05, geometric mean of 100 iterations) for distances from d = 5 bp up to d = 35 bp, whereas 5-mC showed a more modest gradual increase.
Second, we assayed 5-hmC by single-molecule sequencing (SMS), which does not require PCR and microarray hybridization, thus eliminating artifacts due to DNA sequence composition 24 . Genomic DNA from one frontal cortex sample was digested with MspI with or without prior glucosylation and then subjected to poly(A) end-labeling and sequencing (Supplementary Note 2 and Supplementary Table 13) . Direct sequencing confirmed a sharp intronic decrease in 5-hmC at the exon-intron boundary (one-tailed WMW test, median exonic increase in 5-hmC = 4.6% for d = 20 bp; P = 9.2 × 10 −3 ; Fig. 3d and Supplementary Fig. 7 ). We were unable to accurately measure exonintron differences for d = 5 bp, owing to a small number of reads. However, the exonic increase in 5-hmC is evident for cumulative distances larger than 10 bp (Fig. 3d) .
The third approach compared DNA enriched in 5-mC to a fraction depleted in 5-mC (Supplementary Note 2). Each fraction was then subjected to the treatment as in Figure 1a (n = 6 human frontal cortex samples; Supplementary Fig. 8a ). We expected that if 5-mC levels in the brain actually changed across the exon-intron boundary, we would detect a greater cross-boundary change in the 5-mC-rich fraction relative to the depleted fraction. We did not observe such a change at the exon-intron boundary; in fact, intronic levels of 5-mC were slightly higher (P = 0.05, d = 20 bp).
The above three control experiments collectively show that in the human frontal cortex, the change in 5-hmC at the exon-intron boundary exceeds that of 5-mC.
DNA modification at exon-intron boundaries in mouse tissues
To determine whether the change in 5-hmC at exon-intron boundaries is unique to the human frontal cortex, we examined DNA in multiple mouse organs including the mouse brain. Brain samples (from 8-week-old male C57/BL6 mice) were split into frontal cortex and the remainder (including cerebellum and brain stem) (n = 15 samples per group) and analyzed with Affymetrix mouse tiling microarray A. The frontal cortex was analyzed separately to match the brain region investigated in human samples. Consistent with patterns in human brain, at d = 20 bp from the exon-intron boundary, the changes in levels of DNA modifications were mainly due to 5-hmC both in frontal cortex (P = 7.5 × 10 −6 , linear mixed-effects model) and in the rest of the brain (P = 3.0 × 10 −8 ) (Fig. 4a,b and Supplementary  Table 11 ). In these contexts, the change in 5-hmC was not evident at the immediate boundary (for example, P = 0.35 at d = 5 bp in the frontal cortex) but rather was gradual over a region adjacent to the boundary. In contrast, 5-mC exhibited a more dramatic immediate cross-boundary change (P = 9 × 10 −4 at d = 5 bp) (Fig. 4a,b) . 
For non-neural organs, we used the mouse data set described previously in this work (Supplementary Table 5 ; 36 samples from liver, pancreas, kidney and heart; microarrays A and G). In agreement with the markings seen in the human liver, mouse organs of non-neural origin primarily showed changes in cross-boundary densities of 5-mC (d = 5 bp, P = 0.03), with a nonsignificant change in 5-hmC (d = 5 bp, P = 0.25) (Fig. 4c and Supplementary Table 11) . Although both types of DNA modifications show relatively higher exonic densities at the larger periboundary regions (d = 20 bp), the magnitude of change in 5-mC (P = 3.4 × 10 −19 ) exceeded that of 5-hmC (P = 5.7 × 10 −3 ) (Fig. 4c) .
5-mC and 5-hmC at the exon-intron boundary in cell lines
We next assayed a mouse neuronal cell line, which had undetectable (<1%) global levels of 5-hmC measured by TLC (mHypoA-2/24; n = 18 samples, Supplementary Table 12 ). The microarray analysis, which is more sensitive to region-specific differences than is TLC, detected a marginally significant change in 5-hmC at d = 20 bp (P = 0.045, linear mixed-effects model) and a highly significant difference in 5-mC (P = 1.6 × 10 −17 ) (Supplementary Fig. 8b and Supplementary Table 11) .
We also examined boundary differences in a B-lymphocyte data set in which cells were treated with suberoylanilide hydroxamic acid (SAHA). Histone deacetylase (HDAC) inhibitors such as SAHA may promote DNA demethylation 25 and have also been shown to induce changes in pre-mRNA splicing 26 . We examined whether SAHA induces changes in DNA modifications at the exon-intron junction.
Vehicle-treated (no SAHA) B lymphocytes showed no 5-hmC exonintron differences at d = 20 bp (P = 0.27); however, SAHA-treated cells showed an increase in the cross-boundary differences in a manner roughly corresponding to increasing doses of SAHA (P = 0.01, 8.8 × 10 −4 and 3.6 × 10 −4 for 0.01 µM, 0.02 µM and 0.1 µM of SAHA, respectively) ( Supplementary Fig. 9 and Supplementary Table 11).
Exonic 5-hmC and exon inclusion levels
Changes in DNA modifications at exon-intron boundaries may affect exon recognition and exon inclusion levels. To investigate this possibility, we measured 5-hmC as a function of exon inclusion levels, using RNA sequencing data for human frontal cortex and liver 27 (described in Online Methods). Exon inclusion levels were measured as the proportion of transcripts that included a given exon; exons were classified as being alternatively spliced (exon included in ≤ 80% of gene transcripts) or constitutive (exon included in 100% of gene transcripts) (Online Methods). We observed that at d = 20 bp the median 5-hmC density was lower in alternatively spliced exons relative to constitutive exons (P = 0.04, two-tailed WMW test; Supplementary Table 14 shows probe counts and exon sampling), but it was not different for 5-mC (d = 20 bp, P = 0.61). The number of probes at d = 5 bp was too small for a meaningful comparison. The 5-hmC effect was even stronger at the level of the whole exon (P = 8.4 × 10 −5 ); here a marginal change was observed in 5-mC levels (P = 0.025, Fig. 5a ). The increase in 5-hmC was still nearly significant after probes in alternative and constitutive exons were matched for GC content, but in this case the contrast with 5-mC was less pronounced (1,000 iterations, 197 probes per group; geometric mean, P = 0.07 for 5-hmC and P = 0.08 for 5-mC). In the liver, neither 5-hmC nor 5-mC was different among the two types of exons (P = 0.13 for 5-hmC, P = 0.38 for 5-mC, Supplementary Table 14 and Fig. 5b) .
We found separately that average exonic 5-hmC in intronless or single-exon genes was lower than that in genes with multiple exons. For this analysis, we used tiling-array data for control human brains over six chromosomes (arrays E and F, 28 samples, sample median used for each probe; RefSeq gene definitions were used; within each category, duplicate bases were collapsed). We found that exonic 5-hmC in single-exon genes was statistically different from that in multi-exon genes (median, intronless = 0.06 (arbitrary units), multiexon = 0.073; P = 0.026, two-tailed WMW test; n, intronless = 1,256 probes, multi-exon = 22,500 probes). This finding is consistent with an exonic change in 5-hmC due to gene splicing.
Collectively, the results suggest that the density of 5-hmC proximal to splice sites and within exons could affect splicing and exon inclusion levels in the mammalian brain. 
DISCUSSION
In this study, we adapted a 5-hmC detection strategy that uses glucosylation-induced resistance to restriction enzymes for tiling microarray-based mapping of 5-hmC. The glucosylation-based detection of 5-hmC has been successfully used in other studies 7, 8, 28 . Our microarray-based quantification of DNA modifications (verified by TLC) showed significantly higher levels of 5-hmC in brain as compared to other tissues, which is consistent with previous reports 1, 5 . We identified a large number of genes with higher densities of 5-hmC in the brain compared to those in heart, liver, kidney and pancreas. More generally, we discovered a trend whereby 5-hmC in the gene body increases with increased transcription of the corresponding gene, whereas 5-mC decreases. This is consistent with the observation that 5-hmC prevents the binding of transcriptional repressor proteins and is found within actively transcribed genes 7, [29] [30] [31] . Notably, the association between genic 5-hmC and mRNA levels was weakest in the brain (P = 0.17), suggesting that 5-hmC may have other functions in brain cells, in addition to the regulation of gene activity.
Functional annotation analysis revealed a statistical overrepresentation of terms pertaining to synaptic plasticity in genes enriched for 5-hmC in the brain. In particular, annotation clusters were composed of protein groups involved in distinct aspects of synaptic remodeling: ion channels, members of the Rho GTPase signaling pathway and axon-guidance molecules. Notably, most genes in these clusters encode proteins that are functionally located at the plasma membrane rather than being cytosolic. The observation that 5-hmC is overrepresented in the genes controlling synaptic plasticity may shed a new light on the epigenetics of learning and memory. Adult animals with conditional double knockouts of genes encoding DNA methyltransferases 1 and 3b (Dnmt1 and Dnmt3b) in the cerebral cortex showed learning and memory defects in hippocampal-dependent learning tasks, which suggests that changes in DNA methylation occur in post-mitotic neurons 32 . Fear conditioning, an experimental paradigm for emotional learning, results in the demethylation and transcriptional activation of reelin (RELN) 33 . Recent mappings of 5-hmC in the brain have demonstrated generation of 5-hmC and demethylation in response to neuronal activity, but the degree to which the two correspond is not completely clear 9, 34 . In the absence of DNA replication in postmitotic neurons, it is possible that loci undergoing gene reactivation by DNA demethylation accumulate 5-hmC over time. Experiments that map 5-hmC over the course of multiple gene reactivations will explore whether, in the context of synaptic activity, this base marks a stable epigenetic state or is an intermediate in cycles including complete demethylation (that is, conversion to unmodified C).
It is possible that 5-hmC and 5-mC may affect the process of premRNA splicing in addition to transcriptional regulation. Our finding of boundary changes in the examined cytosines replicates earlier observations that used bisulfite sequencing 22, 35, 36 . The separation of the two DNA modifications in our study showed that 5-hmC, rather than 5-mC, accounts for most of the density difference at the immediate exon-intron boundary in human frontal cortex samples. This finding was validated by three control experiments: comparison of GC-matched probes, SMS and methyl binding domain-enriched 5-mC mapping. Whereas the mouse brain samples showed a predominant change in 5-hmC at longer periboundary distances, the main change within the first 10 bp of the boundary was in 5-mC.
The non-neural tissues investigated included human liver and four mouse organs (liver, pancreas, heart and kidney). Whereas these tissues had levels of genomic 5-hmC density measurable by TLC, modification changes at the exon-intron boundary were mainly due to 5-mC. In contrast to the pattern observed in the brain, periboundary changes in 5-hmC were relatively minor in these tissues. These findings suggest that any splicing-related functions that DNA modification may have in non-neural organs are mediated mainly by 5-mC rather than 5-hmC. Separately, we found that B lymphocytes show increased 5-hmC differences at the exon-intron boundary upon treatment with SAHA. SAHA is a chemotherapeutic agent that acts as an HDAC inhibitor and may promote DNA demethylation 25 . As the SAHA dose used in this study is comparable to the plasma concentrations in patients treated for cancer with SAHA 37 , 5-hmC changes at the exonintron boundary may also be expected to take place in vivo. Hence, it is also possible that such changes in 5-hmC in response to HDAC inhibition could also contribute to alternative splicing 26 .
Previous studies have reported that exons are enriched in histone H3 trimethylation at Lys36 and Lys4 and dimethylation at Lys27, relative to flanking intronic regions [38] [39] [40] . These modifications can recruit splicing regulators to affect alternative splicing of nascent transcripts 41 . Whereas the resolution of histone maps is limited by the size of nucleosomal DNA (147 bp), our DNA modification studies have identified changes in modification levels within 20 bp (and in some cases within 5 bp) surrounding the exon-intron boundary. This precision argues for a specific effect at the exon-intron boundary as well as a possible difference between exons and introns as a whole, as described in earlier studies 34 . Our finding that 5-hmC densities are lower in alternatively spliced exons relative to constitutive exons complements the observation that trimethylated histone H3 Lys36 is less enriched in alternatively spliced exons 39, 42, 43 . DNA methylation has been shown to modulate exon inclusion levels by influencing the rate of transcript elongation in B lymphocytes. Lack of DNA methylation can promote exon inclusion by causing 'pauses' in RNA polymerase II-mediated elongation, and it may also affect RNA polymerase II elongation-dependent changes in alternative splicing by affecting the binding of the transcriptional repressor CTCF 44 . There may also be other mechanisms by which DNA methylation could influence exon inclusion levels, for example, through the recruitment of splicing factors by methyl-binding proteins.
Our findings suggest that tissue-specific distributions of 5-hmC or 5-mC at the exon-intron boundary and within genes may simultaneously influence both transcription and splicing. The direction of the influence remains unclear, as transcription and splicing may also affect epigenetic DNA modifications, and mechanisms for cross-talk likely exist between epigenetic regulation, splicing, and transcription 45, 46 .
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Data have been deposited in GEO, with accession numbers GSE40167 (for the SuperSeries), GSE40166 and GSE40158.
ONLINE METHODS
Experimental outline. Our experimental strategy exploited the ability of the BGT enzyme of T4 phage to transfer a monomeric glucose residue from uridine diphospho-α-D-glucose (UDP-Glc) to the exocyclic hydroxyl group of 5-hmC in double-stranded DNA. This specific addition of a glucose moiety to 5-hmC blocks access of methylation-insensitive endonucleases to their target sites, thus making the DNA fragment resistant to digestion 13, 14 . Here we used the isoschizomer restriction enzymes HpaII and MspI. HpaII cleaves DNA only when the CpG dinucleotide is unmethylated at CCGG, whereas MspI cleaves the CCGG sites independently of any natural CpG modification, including 5-mC and 5-hmC 47, 48 .
Microarray experiments were performed as illustrated in Figure 1 . Each genomic DNA sample was split into three parts, one of which was subjected to BGT glucosylation and two of which were not glucosylated (details in Supplementary Note 2). One unglucosylated part was treated with MspI, serving as a baseline for digestion. The second unglucosylated part was treated with HpaII, which spares any modified cytosines at the recognition site. The BGTglucosylated part was treated with MspI, and 5-hmC was measured as the decrease in digestion of this part, relative to the unglucosylated part. The difference between HpaII and MspI restriction efficacy on unglucosylated DNA reflected 5-hmC and 5-mC combined, and the difference between the former measurement and 5-hmC was the measure of 5-mC.
Sample description. This study used data sets from various mouse organs, human brain and liver and two cell lines. Male C57BL/6J mouse brain tissues (frontal cortex and remaining brain) and other organs (liver, pancreas, kidney and heart) were obtained from 8-week-old mice (Supplementary Table 5 Supplementary Table 10 . Genomic DNA isolation was performed by standard proteinase K digestion and phenol-chloroform extraction.
Sample preparation for glucosylation and restriction digestion. From each tissue, gDNA was sheared to 200-bp fragment length by using a Covaris S2 sonifier (Covaris, USA). Sheared DNA was end-filled in the presence of T4 DNA polymerase (5 U) at 11 °C for 20 min and purified using PN buffer from the QIAquick Nucleotide Removal Kit (Qiagen). The purified 1 µg of blunt-ended DNA was ligated with A1-25 adaptors (10 µM) ( Supplementary  Table 15 ) in the presence of T4 DNA ligase (10 U) at 22 °C for 3 h, inactivated at 65 °C for 10 min and purified with the QIAquick Nucleotide Removal Kit. One-third (~300 ng) of the purified DNA was treated with 200 µM uridine-5′-diphospho-α -d-glucose (UDP-Glc, Sigma), 80 ng BGT 49 in 100 mM Tris-HCl, pH 8.0, and 25 mM MgCl 2 for 3 h at 37 °C and purified again. Thereafter, 200 ng of glucosylated DNA and 200 ng of untreated DNA were subjected to MspI digestion in a final volume of 20 µl for 12 h at 37 °C, followed by enzyme inactivation at 80 °C for 10 min. The same protocol was performed on 200 ng of untreated DNA using HpaII. Following the observation that some 5-hmC may be resistant to MspI digestion 50 , we used 10 units of enzyme (50-fold surplus of the enzyme over the DNA substrate, digested for 12 h). Restriction enzyme-digested genomic DNA from each scenario was PCR amplified using adaptor-specific primers (Supplementary Table 15 ). Amplified PCR products were fragmented, biotin-labeled, hybridized on Affymetrix whole-genome tiling arrays (Supplementary Table 1 ) and scanned as described in the Affymetrix Chromatin Immunoprecipitation Assay protocol (http://media.affymetrix.com/ support/downloads/manuals/chromatin_immun_ChIP.pdf).
Microarray data preprocessing. We distinguished between three types of probes on the whole-genome tiling microarray: 'target probes' , which contain the restriction site CCGG, 'flanking probes' , which do not contain the recognition sequence but could lie up to 200 bp upstream or downstream of a target probe (sheared DNA fragments were, on average, 200 bp) and 'non-target probes' that neither contain a target sequence nor are within 200 bp (on either side) of the target sequence. Nontarget probes are unaffected by enzymatic cleavage and therefore can be used as a baseline for array normalization. After comparing different array preprocessing algorithms (Supplementary Note 1) , we chose to use a sequencebased algorithm after a previous study 16 .
The model (Supplementary Note 2, equation (1)) was applied to nontarget probes matched proportionally to target probes by GC content. Normalized intensities were obtained by subtracting the fitted value from raw probe intensities, resulting in a normal distribution of probe-level intensities. Each chip was independently normalized. All downstream analyses were carried out at the single-probe level (that is, without windowing or peak-calling) and solely on target probes (henceforth referred to as 'probes'). 5-hmC was measured as the log difference between glucosylated DNA and native DNA, following treatment with MspI (Fig. 1a) . The sum of all the DNA modifications was measured as the log difference between HpaII-treated unglucosylated DNA and MspI-treated unglucosylated DNA. 5-mC was estimated by the difference between all DNA modifications and 5-hmC.
Following normalization, probes overlapping repeats were excluded (RepeatMasker, simple repeats and segmental duplications; genomic annotations from UCSC genome browser, build mm8 for mouse, hg18 for human). Information on arrays and probe counts are listed in Supplementary Table 1. Unless otherwise specified, analysis was done using R software and BioConductor 51 .
For the exon-intron boundary analysis, probes were required to have a CCGG in both the Affymetrix probe sequence and the chromosomal sequence downloaded from UCSC; probes that did not meet this criterion were excluded.
Identification of 5-hmC enriched regions in mouse brain. Probes were filtered for those overlapping genes on either strand (RefSeq genes (refGene) downloaded from UCSC, mm8; range between txStart and txEnd columns). Probes overlapping multiple genes (as defined by MGI gene symbol) were excluded, as were genes containing exactly one probe, resulting in 73,461 probes over 4,357 genes (range, 2-238 probes per gene; mean, 17). A repeated-measures ANOVA was conducted on probes in each gene, with tissue as a between-groups factor ('brain' , 11 samples; 'other' , 36 samples; liver, heart, kidney, pancreas, 9 samples each) and the biological sample as a within-groups error term. Probes within a gene were neither averaged across samples nor collapsed within a gene. Genewise nominal P values were adjusted using the Benjamini-Hochberg method of false-discovery-rate correction (BH; α = 0.01). Of genes with Q < 5% (n = 730), all but one had higher 5-hmC in the brain, and these are therefore called 'brain enriched' .
Calculation of exon-intron boundary differential. Boundary regions were defined as regions within a certain distance on both sides of an exon start or end (RefSeq genes, internal exons only). Where multiple exons had the same genomic extent (that is, location on chromosome, start and end), only one such exon was retained. For each probe, the distance from the modifiable second C (of CCGG) was computed to the nearest exon (or intron) boundary; this value is the boundary distance of the probe (a value of 0 was exonic in these calculations). Statistics were computed on probes that lay ≤5 or ≤20 bp on either side of the junction. The result at a distance of 20 bp reflected the general trend observed at the boundary, whereas that at 5 bp reflected immediate cross-boundary change. A linear mixedeffects model 52 was used to test probe intensity differences between the exonic and intronic side of the junction. Junction side was used as the fixed-effects term, and array type and sample were treated as random-effects terms (Supplementary  Note 2) ; α = 0. 025 was used to indicate a statistically significant result.
Correlation of 5-hmC with exon inclusion levels. RNA-seq results from liver and cortex 27 were analyzed to identify cassette exons and their respective inclusion levels. Thresholds used to identify cassette exons are described in Supplementary Note 2. The inclusion level of an exon was defined as the proportion of gene transcripts in which the exon was present 
) + × + 2 2 1 sum C sum i j C C C where C i is any possible splicing donor upstream from the alternative exon (including C 1 ), and C j is any possible splicing acceptor downstream from the alternative exon (including C 2 ). Exons with multiple acceptor or donor splice npg sites and those not supported by RNA-seq were excluded. We defined an exon as alternatively spliced if the inclusion level was less than 80% and as constitutive if inclusion was 100%. DNA methylation was assessed in those exons that overlapped 'target probes' (probes containing CCGG) (probe counts are shown in Supplementary Table 14) . Methylation levels of exons were computed at the whole-exon level and at d = 20 bp away from the boundary. Sample-averaged median probe intensities were compared between probes overlapping constitutive and alternative exons (two-tailed WMW test, α = 0. 05). 
